EF Hutton Reiterates Buy on Coya Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Elemer Piros reiterates a Buy rating on Coya Therapeutics (NASDAQ:COYA) and maintains a $28 price target.
June 07, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Elemer Piros reiterates a Buy rating on Coya Therapeutics and maintains a $28 price target.
The Buy rating and maintained price target by EF Hutton analyst Elemer Piros indicate a positive outlook for Coya Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100